Archive · 25 Sep 2025
Laurus Labs CEO Sees Huge CDMO Opportunity in India
Laurus Labs' CEO, Satyanarayana Chava, says India has a big chance to grow its contract development and manufacturing (CDMO) industry.
This means companies can do research and make medicines for others.
He mentioned that the industry could grow bigger if rules are made easier.
Laurus Labs is investing a lot in research and development, especially in Genome Valley, India.
They are also building new facilities.
Laurus Labs makes medicines for people with HIV.
The company hopes to reach certain financial goals soon, and they see more opportunities coming up.
Laurus Labs CEO sees huge opportunity for India's CDMO industry.
Regulatory bottlenecks are potential challenges to growth.
Laurus Labs has invested heavily in R&D and manufacturing facilities.
The company is experiencing increased requests for proposals.
Laurus Labs aims to reach ₹2,000 crore in CDMO revenue by FY26.
- Who
- Satyanarayana Chava, CEO of Laurus Labs.
- What
- Discussed the growth potential of India's CDMO industry.
- When
- FY26 is the target year for revenue and margin goals.
- Where
- Genome Valley and India.
- Why
- To provide insights on the Indian CDMO industry's potential and challenges.
- Company
- Laurus Labs
- CEO
- Satyanarayana Chava
- R&D Investment
- ₹500 crore so far
- CDMO Revenue Target (FY26)
- ₹2,000 crore
- EBITDA Margin Goal
- Around 25%
- HIV Medicine Supply
- APIs and formulations for one-third of global population